VISTAGEN THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
VISTAGEN THERAPEUTICS, INC. (VTGN) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $0.52 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-08-14
- VISTAGEN THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2026-06-30 was $0.52, a 72.19% decline year-over-year.
- VISTAGEN THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-06-30 was $1.87, a 47.32% decline year-over-year.
- VISTAGEN THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2024-06-30 was $3.55, a 193.39% increase year-over-year.
- VISTAGEN THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2023-06-30 was $1.21.
- VISTAGEN THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2026 was $2.21, a 35.94% decline from fiscal 2025.
- VISTAGEN THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $3.45, a 21.59% decline from fiscal 2024.
- VISTAGEN THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $4.40, a 45.68% decline from fiscal 2023.
- VISTAGEN THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $8.10, a 77.50% decline from fiscal 2022.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $0.52 10-Q · filed 2026-08-14 | ||||
| 2026-03-31 | $2.21 10-K · filed 2026-06-15 | ||||
| 2025-12-31 | $2.20 10-Q · filed 2026-02-12 | ||||
| 2025-09-30 | $1.98 10-Q · filed 2025-11-13 | ||||
| 2025-06-30 | $1.87 10-Q · filed 2026-08-14 | ||||
| 2025-03-31 | $3.45 10-K · filed 2026-06-15 | ||||
| 2024-12-31 | $3.49 10-Q · filed 2026-02-12 | ||||
| 2024-09-30 | $3.51 10-Q · filed 2025-11-13 | ||||
| 2024-06-30 | $3.55 10-Q · filed 2025-08-07 | ||||
| 2024-03-31 | $4.40 10-K · filed 2025-06-17 | ||||
| 2023-12-31 | $3.62 10-Q · filed 2025-02-13 | ||||
| 2023-09-30 | $3.46 10-Q · filed 2024-11-07 | ||||
| 2023-06-30 | $1.21 10-Q · filed 2024-08-13 | ||||
| 2023-03-31 | $8.10 10-K · filed 2024-06-11 | ||||
| 2022-03-31 | $36.00 10-K · filed 2023-06-28 | $1.20 10-K · filed 2022-06-23 | |||
| 2021-03-31 | $0.87 10-K · filed 2022-06-23 | ||||
| 2020-03-31 | $0.73 10-K · filed 2021-06-29 | ||||
| 2019-03-31 | $1.15 10-K · filed 2020-06-29 | ||||
| 2018-09-30 | $0.98 10-Q · filed 2018-10-29 | ||||
| 2018-03-31 | $1.10 10-K · filed 2019-06-25 | ||||
| 2017-03-31 | $2.69 10-K · filed 2018-06-26 | $2.68 10-K · filed 2017-06-29 | |||
| 2016-03-31 | $7.09 10-K · filed 2017-06-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B |